BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine
24 févr. 2022 08h30 HE
|
BioDelivery Sciences International
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology ...
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
14 févr. 2022 06h30 HE
|
BioDelivery Sciences International
Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock’s closing price of $3.64 on February 11, 2022 and a 65% premium to...
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
20 janv. 2022 08h00 HE
|
BioDelivery Sciences International
Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as...
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032
20 déc. 2021 16h27 HE
|
BioDelivery Sciences International
RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and...
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
03 nov. 2021 08h00 HE
|
BioDelivery Sciences International
Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of...
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
21 oct. 2021 08h00 HE
|
BioDelivery Sciences International
RALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021
20 oct. 2021 08h00 HE
|
BioDelivery Sciences International
RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic...
BioDelivery Sciences International to Host ELYXYB™ Investor Day
30 sept. 2021 08h00 HE
|
BioDelivery Sciences International
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Virtual Event on October 14, 2021 RALEIGH, N.C., Sept. 30, 2021 ...
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada
09 sept. 2021 08h30 HE
|
BioDelivery Sciences International
Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults ...
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference
07 sept. 2021 09h28 HE
|
BioDelivery Sciences International
RALEIGH, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic...